Tissue plasminogen activator (tPA) is a protein involved in the breakdown of blood clots. It functions by converting plasminogen into plasmin, which then degrades fibrin, the main component of blood clots. This process is essential for the dissolution of blood clots and restoring blood flow in cases of thrombosis or embolism. Research in the area of tissue plasminogen activator focuses on understanding its role in various physiological processes, developing treatments for conditions involving abnormal blood clotting, and exploring its potential applications in therapeutic interventions. tPA is commonly used as a thrombolytic agent in the treatment of ischemic stroke, myocardial infarction, and pulmonary embolism. Studies also investigate the potential side effects and limitations of tPA therapy, as well as exploring new strategies to improve its effectiveness and safety. Additionally, researchers are exploring the potential of tPA in other therapeutic areas, such as cancer treatment and neurodegenerative disorders.